Member Info for violindog

TF...thanks for your kind words : )

Hi Cleanerworld, indeed, Scancell surely have had enough time to reschedule an investors presentation . Two were planned and required cancelling due to the audit issue. Wonder why they have not ?

Paul, very, very true its just been such a long slog now . I'm in the ten year + club also Matt !! I do believe amazing progress has been made recently, both with the science and appointments ...its incredible that we have 2 drugs in trial partly paid for by shareholder fundraising keeping the lights on over the years. I would be beyond gutted if I sold out / reduced signisicantly just prior to a mega deal landing ....but increasingly I an inclined / need to set the end of H1 next year as an exit point.

Still time for ink to dry this year before the Christmas and NY break....so good luck fellow investors and staff at Scancell!!

Bermuda, you obviously know far more than myself , but your timeliness are very depressing. The 5million was very welcome and has gone a long way to extend the cash runway and help develop the Scancell pipeline. Obvious value wad added to Scancell resulting from this deal , but not reflected in the SP . I take from Bermudas comments we are potentially ages away from further milestone payments . This would therefore also apply to any additional deals related to this platform....so it's all about upfront payments. I still consider, by comparison , 5m was a pretty low value deal so I hope the new team will negotiate harder . We have been told of interested parties so fingers crossed we may get a decent result.

Increasingly , its looking like SCIB / Moditope may currently be our best hope of a mega deal unless we need to wait years for version 2 of both. I'm beginning to understand why Bermuda reduced his holdings. Its balancing our amazing products against the time to develop them. Many of us thought this was finally the "transformational year" but If Scib /Moditope need version 2 to attract bidders then the timeline gets extended and investors like Berm and Crumbs reduce holdings.

The only hope for a quick return is a bid for Scancell from a pharma who wants to get in early doors. I'm still holding out for this to happen especially after the recent conferences showcasing the company. As a very LTH with an ever decreasing timescale for investment ...I'll give it to the end of H1 next year when we should hopfully get a boost from results of modi+checkpoint and Scib.

Rigga, yes , hopefully we will hear something soon. You can also add the time spent on due diligence Genmab did prior to the deal, so infact they have had much longer than a year to progress this. Its also almost a year since the last AGM when we were good as promised further deals. Time ticks on .

Guess he has to fund his awfull foreign policy somehow.

GF123, hi, well from my point of view something commercial has to happen soon. I can't wait out more years while Modi-2 / iScib is developed. As a LTH I'm slightly imune to hearing the phrase "near term commercial inflection points". Scancell does appear to have an increased business focused drive with the recent appointments. It would be wonderful if SCIB and / or the mAbs finally landed a significant deal .

Cooley’s global life sciences capabilities are unmatched. The firm represents nearly 2,500 public and private life sciences clients worldwide, including almost 50% of the Nasdaq Biotechnology Index. Clients include innovative biotech and specialty pharmaceutical companies at the forefront of new technologies, including cell and gene therapies, artificial intelligence-led drug discovery and new vaccine technologies. Cooley was recently named Law360’s Life Sciences Practice Group of the Year and has been the #1 venture capital law firm for biotech and pharma venture financings for the last decade (PitchBook). Cooley also is the #1 firm for issuer-side life sciences IPOs (Deal Point Data) – a title held since 2000 – and was named the Licensing & Collaboration Firm of the Year by LMG Life Sciences in 2022

Is there going to be an Investors Presentation?

Like this part ...

OUTLOOK

Given the significant clinical and commercial milestones achieved in the period, positive early efficacy data, and

with sufficient resources to fund our current strategy, the Company is confident it will achieve its near-term clinical

milestones. Key milestones for the following 18 months include:

 Second stage of SCOPE study in advanced melanoma with SCIB1 anticipated to complete recruitment by

the end of 2023 with data available in H1 2024

 iSCIB1+ planned to be included in the SCOPE study. Protocol amendment pending MHRA approval

 Phase 2/3 seamless adaptive registration trial with SCIB1 or iSCIB1+ to begin in 2024

 ModiFY trial to continue recruitment in the expansion cohorts with early clinical data expected in 2024

 Continue to assess out-licensing options for the GlyMab® and AvidiMab® platforms providing a source of

non-dilutive cash to drive our other assets forward in development

The Board is pleased with the progress that the Company has achieved over the period and would like to thank

our shareholders once again for their continued support.

As chief whinger of this group ....very pleased. Hopefully by the time of the Investigator Presentation, LD can announce further Genmab payments ...the only explanation for the extended cash runway. This would hopefully go down very well with the audience.

Well done dragon on your topup, and you moonparty..you based in the USA Dragon ?

Agree with you, some may well be selling today and last week as they don't want to get "locked in " a suspension... if this happens. If you make money on a trading punt , then good luck...hope it works out for you. Scancell won't be " immune "from statutory regulation despite immunotherapy : ))

TF, fingers crossed everything audit related is sorted ASAP. The outstanding science and current trials continue as does recruitment ...re the latest job advert.... These, accompanied by any further deals, will be the SP driver we are all hoping for.

The audit issue just got me wound up..Scancell never seam to get lucky and it always seams to be external factors that dent sentiment , like the US blocking the Ichor gun etc. Frustration got the better of me .

...what is so hard to understand about a legal deadline with a fixed date and statutory consequences...

I shouldn't think that Diggle would be very pleased to be a director of a company that failed to complete accounts on time.

As we are aware from the RNS....totally NOT any issue with Scancell ...but failing to have the accounts in on the 29th, Tuesday, will have implications for Scancell and the directors.

I would expect an outfit like Redmile / Vulps would have included a clause to protect their investment should such an event arise. I expect that as long term investors they will hopefully be understanding of the issue .

Ray, if you open the link from WTP, under the section "Avoiding a penalty", you can look up Scancell Holdings and the result states accounts are due by the 31st October....So, by midnight monday at the latest. Hopefully those incompetent auditors have filed over this weekend. I expect an RNS either way on Monday.

Scancell really do need to drop this millstone from around their neck

Consultancy UK 14th July 2023

"In the 2023 assessment, the FRC found that overall, 77 of 100 audits inspected for the last financial year were "good" or required only limited improvement, reflecting a 10% increase compared with 67% in 2020. However, among that there were some firms performing well below that average.

According to the FRC, BDO and Mazars continue to lag behind the wider pack, with "unacceptable" recurring findings at BDO in particular. This is similar to last year’s findings, when it was speculated that their performance was related to “growing too fast”, and taking on “high risk work” from clients dropped by Big Four auditors – who were allegedly looking to de-risk their portfolios, and so boost their performance averages.

"It is disappointing that there are still significant areas of their [BDO and Mazars] work that need to be addressed and the FRC will continue its increased level of supervision, requiring them to take further action to raise the quality of their audits in certain areas," stated Sarah Rapson, FRC deputy chief executive.

https://www.consultancy.uk/news/34804/mazars-and-bdo-receive-watchdog-warning-not-to-drop-risky-clients

WTP....

"Underlying reason is not material according to latest RNS' so no fault on Scancells side"...

Yes...no fault on Scancell’s side... but the SP of Scancell has been punished on each audit RNS.. we will be lucky to hold 13p...these bunch of incompetent bean counters need to be be sacked ASAP.

With no official notification from Scancell that they attended ESMO, which is very strange as it was almost back to back with the WVC.... and you do have think...well.... why not attend ? I hope against hope that perhaps they signed off a deal at the WVC and it therefore wasn't necessary to attend ESMO and network . Just a thought while waiting for the rugby.

Dragon....personally...whatever it takes to get the SP elevated ! The hinted promises from last years AGM have failed to materialise and every progressive RNS of late fails to maintain any momentum. We have collectively always said data will see us through but the SCOPE RNS hasn't done anything.. as yet. I don't think many LTHs could wait out the extra years developing iScib2/modi2 accompanied by a stagnant SP.

Hopefully the data from modi1 will trigger a deal of some sort?? I simply can't wait out another year of promising data with nothing reflected in the SP, let alone years developing Scib/modi2.

I have considerably reduced my exit price from £1 to 50 pence.

Sorry to be gloomy...but time is very much against me : ((